基于HPMC的硬囊的干燥过程:视觉实验和数学建模
Chuqi He1,2, Yucheng Yang1,2,3, Mi Zhang1,2
1Department of Chemical and Pharmaceutical Engineering, School of Chemical Engineering, Huaqiao University, Xiamen 361021, China.
Gels (Basel, Switzerland)
|June 27, 2023
概括
这项研究使用低场磁共振成像 (LF-MRI) 和修改后的模型来了解植物性凝囊干燥. 研究结果揭示了对于工业囊生产至关重要的水分扩散动态.
科学领域:
- 材料科学 材料科学 材料科学
- 化学工程是化学工程的重要组成部分.
- 制药技术 制药技术 制药技术
背景情况:
- 植物性多糖体凝是一种用于医学的硬囊的新材料.
- 目前的制造,特别是干燥,阻碍了这些囊的工业规模生产.
研究的目的:
- 为了研究植物性多糖凝硬囊的干燥过程.
- 为干燥过程中的水分含量开发一个预测模型.
- 了解影响这些囊中的水分扩散的因素.
主要方法:
- 使用低场磁共振成像 (LF-MRI) 来可视化干燥期间的水分分布.
- 根据菲克第二定律开发了一个修改后的数学模型,将动态有效湿度扩散率 (D_eff) 纳入其中.
主要成果:
- 修改后的模型准确地预测囊的水分含量在±15%以内.
- 有效的湿度扩散率 (D_eff) 从3 × 10−10到7 × 10−10 m2·s-1不等,随着时间的推移不规则地变化.
- 温度升高和相对湿度降低加快了水分扩散.
结论:
- 这项研究为植物性多糖体凝的干燥行为提供了基本的见解.
- 了解这些干燥动态对于优化基于HPMC的硬囊的工业制造至关重要.
相关概念视频
01:13In Vitro Drug Dissolution: Compendial Testing Models I
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
01:09In Vitro Drug Dissolution: Compendial Testing Models II
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients, maintaining...
01:18Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...